Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC-FOLFOX vs TACE in Large Hepatocellular Carcinoma
NCT02973685Phase 3Completed
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2016
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 24 months. Started Oct 2016; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02973685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973685.